| Name | Title | Contact Details |
|---|
Concordia Pharmaceuticals is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.
Noninvasive monitoring that enables less invasive care. My care setting is: MORE Noninvasive monitoring that enables less invasive care. My care setting is: MORE
RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tis...
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.